6 August 2021 Prof Lynn Morris presented results from the antibody-mediated prevention trial that tested the ability of VRC01 broadly neutralising Ab(specific for the HIV envelope protein CD4 binding site and has a wide coverage of HIV subtype B and C strains. Participants in the AMP trials received 10 doses of VRC01...
2021
IUIS Webinar: HIV prevention- antibodies and vaccine development (part 1)
5 August 2021 Prof. Lynn Morris began her talk comparing the HIV and SARS-Cov-2 epidemics, at the peak of the HIV epidemic approximately annual mortality was 1.8 million deaths reported due to HIV/AIDS. Fortunately, HIV-associated mortality has drastically decreased due to the successful roll-out of anti-retroviral treatment.
Potent neutralising antibodies against SARS-CoV-2 variants of concern.
2 August 2021 Wang and colleagues aimed to isolate potent neutralising antibodies that have activity against VOCs as well as other SARS-Cov-2 variants, as well as determine whether these potent nAbs have therapeutic potential and can reduce resistance development. Researchers isolated SARS-CoV-2 specific antibodies...
World Hepatitis Day: proof of concept HCV nanoparticle vaccine
Hepatitis C virus (HCV) is a genetically diverse including six major genotypes and more than 86 subtypes, additionally, HCV has a rapid mutation of HCV leads to viral quasispecies that can escape the immune response in infected individuals. This makes developing HCV vaccines very challenging.
Immunogenicity of heterologous SARS-CoV-2 vector vaccine prime-mRNA vaccine boost vaccination strategy
There are currently multiple trials that are investigating different strategies such as SARS-CoV-2 vector vaccine prime followed by an mRNA vaccine boost and vice versa. In this summary, we report on findings by Borobia et al., 2021,
Global Immunotalks Highlight: Immune responses after dengue virus infection: friend or foe?
We highlight Global-ImmunoTalks webinar featuring Dr Tineke Cantaert, Dr Cantaert began her talk highlighting the main focus of her research lab: Investigation of adaptive immune responses to Arboviruses.
What does HLA-DR expression on CD4 T cells indicate?
HLA-DR is a molecule typically expressed by antigen-presenting cells and is associated with antigen presentation. Interestingly HLA-DR is also expressed on T cells and has been associated with T cell activation. However, why and how activated T cells express HLA-DR is not fully understood.
IUIS-Immunopaedia-Frontiers Webinar: Immunopathology of COVID 19 lessons from pregnancy and from ageing
Prof Cossarizza webinar focused on COVID-19 immunopathology during pregnancy and ageing. He began his talk by highlighting the role inflammation plays in ...
Could infection with other viruses provide protection from SARS-CoV-2?
9 July 2021Cheemarla et al, studied Rhinovirus (RV) infection before SARS-CoV-2 exposure and they found that RV infection provided protection from SARS-CoV-2 replication by accelerating ISG responses.
Microbes prime foetal immune cells during early human development
7 July 2021Mishra, A. et al, found live bacterial strains including Lactobacillus and Staphylococcus which activated memory T cells in the foetal mesenteric lymph nodes. This suggests that microbes do play a role in foetal immune-priming.